The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) on July 24, 2025. This approval, designated BLA 125514 S-178, was granted based on demonstrated efficacy, as submitted by sponsor Merck Sharp Dohme.
Background
Pembrolizumab, marketed as Keytruda, is an established immunotherapy drug. Supplemental applications for existing approved biologics like Keytruda typically seek to expand the drug's label to include new indications, patient populations, or dosing regimens. This specific supplemental approval was granted based on new efficacy data.
What this means
An FDA supplemental approval based on efficacy for an already approved drug like Keytruda signifies that new clinical data has supported its effectiveness for an additional therapeutic use. While the specific new indication or patient population is not detailed in this record, such approvals are crucial for expanding treatment options and optimizing patient care. Clinicians and researchers will monitor for further details regarding the expanded label to understand the full implications for patient management.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA) database, specifically regarding supplemental application BLA 125514 S-178 for Keytruda (pembrolizumab). The approval date was July 24, 2025, and the details are available on accessdata.fda.gov.